We saw some more low volume drift and no real news to break through the summer doldrums, which seems to be in effect. I think this will probably be the rule for the rest of the summer with choppy, low volume trading as the rule punctuated but news filled days that drive the sector (or […]

June 8 Biotech Update

Yesterday was surprisingly good, although so far we have not really had a nice follow through to start today. That being said the rally started to pick up steam later in the day, so perhaps we will follow the same pattern. If we continue to trade well in lieu of the negative news yesterday, then […]

June 7 Biotech Update

Today is going to be a real test of the sector with all the negative news that came out. I am sure some will try to call this the ASCO hangover but any selling today has little to do with ASCO. The sector has had a good run and I would not be surprised to […]

June 2 Biotech Update

I missed a day but not much happened. The sector continues to do well and it seems to be slowly turning sentiment around. The one negative (or perhaps positive) is that the ISI traders noted that there is still not buying demand and the move seems to be driven by a lack of sellers and […]

Cup O’ Joe – May SRPT Edition

***Joe Gantoss relies on knowing more, either through technical analysis & charts or DD & research.*** Well, SRPT has delayed their decision past the PDUFA, destroying the weekly out-of-the-money (OTM) options traders counting on a decision.  I debated making a play, but ultimately I was not comfortable.  But that trade is over, where do we […]

May 25 Biotech Update

The market continues higher and the sector with it. We seem to be moving away from the previous lows with broader participation with SMID and large caps. This market continues to be hated and I suspect people are still underinvested in healthcare. This all makes me marginally more bullish in the near term even though […]

April 27 Biotech Update

This week seems to have started like last week. I think it was actually last Tuesday that the sector suddenly took a dive on no real news and yesterday was certainly not a good day. It remains to be seen if this weakness will continue as we are entering into earnings that could help the […]

April 21 Biotech Update

I think the best description of the sector is listless and uncertain. The price action has been mixed but more than anything else, there has been a significant lack of volume. No one wants to buy or sell biotechs and so they have been drifting with some good days and some bad days. We are […]

March 22 Biotech Update

It looks like the sector did not fall off a cliff and perhaps has been finding some support. We still have the recurring question of whether this is real buying or simply short covering. As has been the case, I fall in the camp that this is short covering at least among the smaller caps. […]

SRPT – YEAR 4 DATA ANALYSIS

  YEAR 4 DATA ANALYSIS Review of Eteplirsen to treat DMD By: @boscaptn, et al.   Compiled From SAREPTA Public Data For Week 216 (Year 4) of Study 201/202 for Exon 51   Disclaimer: NO FINANCIAL ADVICE – The Information in this report is provided for education and informational purposes only, without any express or […]

Cup O' Joe – SRPT AdCom

  ***Our trading analyst Joe Gantoss relies on knowing more, either through technical analysis & charts or DD & research.*** Thesis: Joe has done a lot of research on SRPT. Despite some FDA headwinds, he believes the AdCom will at least be moderately positive for SRPT. But there is some downside risk, so there is […]

Sarepta: Is Eteplirsen Dead?

This was originally going to be titled “Ahead of the AdCom” but that no longers seems fitting. The highly anticipated Advisory Committee meeting originally scheduled for Friday January 22 was canceled due to blizzard conditions. Extremely negative reviews in Briefing documents [link] from the FDA are leading many to expect a denial for Eteplirsen’s drug […]

January 21 Biotech Update

So we have some biotech to talk about (finally) and the sector had a nice rally off the lows yesterday but we are not out of the woods by a country mile. At this point, however, it looks to be setting up as at least a tradable bounce but more ideally we would want it […]

January 20 Biotech Stock Update

Not much news as most people wait on SRPT questions as the panel approaches but even then there will not be a lot of new information in the questions (yes, maybe it signals what the FDA is thinking but that is likely too much to ask for a set of voting questions but not impossible). […]

January 15 Biotech Update

I hope everyone enjoyed the move yesterday as it looks like it was only a quick respite to the relentless decline in 2016. Sentiment will eventually change but the hopes of a V shaped recovery are fading fast. If we can avoid making new lows, then there might be some positive to come out of […]

January 14 Biotech Update

So the sector has been struggling a little during JPM. I think many hoped (including me) that good news out of JPM would be a nice catalyst to flip sector sentiment but we essentially saw the opposite with all news (good and bad) being sold. At this point, it is clear that the selling has […]

January 5 Biotech Update

While the market recovered a little into the end of the day yesterday and had a slight positive bias this morning, it is still not looking too healthy. I am not sure if this is simply people selling or buyers being afraid to step in. In terms of the sector, I still think JPM will […]

November 25 Biotech Update

Trading is slow this week but news is not. Yesterday was better but I still think it is too early to call the sector back but at the very least I believe is has found its footing. Interestingly it seems that the SMID caps are outperforming the larger caps (finally) although they have a lot […]